Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

131.39USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$131.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,871,152
52-wk High
$137.07
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
Friday, 16 Jun 2017 01:06pm EDT 

June 16 (Reuters) - Genmab A/S :Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.Genmab - will receive milestone payments totaling $25 million from Janssen in connection with approval & first commercial sale of darzalex under newly expanded label.Genmab - approval and related milestones do not impact financial guidance issued by Genmab on May 10, 2017.  Full Article

J&J completes $30 bln takeover of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - Actelion Ltd :Johnson & Johnson completes acquisition of Actelion.Actelion announces completion of acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash.  Full Article

Johnson & Johnson announces completion of acquisition of Actelion
Friday, 16 Jun 2017 01:00am EDT 

June 16 (Reuters) - J&J : :Johnson & Johnson announces completion of acquisition of Actelion.Expects transaction to add about $1.3 billion in sales for 2017 and be accretive to 2017 adjusted earnings per share by approximately $0.07.  Full Article

Minerva Neurosciences enters amendment to co-development and license agreement with Janssen Pharmaceutica NV
Wednesday, 14 Jun 2017 04:38pm EDT 

June 14 (Reuters) - Minerva Neurosciences Inc ::Minerva Neurosciences - on June 13, co entered amendment to co-development and license agreement between company and Janssen Pharmaceutica NV.Minerva Neurosciences Inc - amendment to co-development and license agreement related to company's min-202 product candidate.Minerva Neurosciences Inc - pursuant to amendment, minerva will gain global strategic control of development of min-202 to treat insomnia .Minerva Neurosciences Inc - pursuant to amendment janssen will forego its right to royalties on min-202 insomnia sales in Minerva territories.Minerva Neurosciences Inc - Janssen has agreed to make an upfront payment to Minerva of $30 million upon effectiveness of amendment.Minerva Neurosciences Inc - Minerva also entered into a stock repurchase agreement with Johnson & Johnson Innovation-JJDC Inc.Minerva Neurosciences Inc - Janssen has also agreed to make a $20 million payment at start of a phase 3 insomnia trial for min-202.Minerva Neurosciences Inc - Janssen has also agreed to a $20 million payment when 50pct of patients are enrolled in the trial for min-202.Minerva Neurosciences - to repurchase all of about 3.9 million shares of Minerva stock held by Johnson & Johnson Innovation-JJDC Inc at $0.0001 per share.Minerva Neurosciences-Janssen agreed to waive remaining payments due from Minerva for phase 2 development of min-202, which total about $13 million.  Full Article

Metlife names Susan Podlogar Chief Human Resources Officer
Monday, 12 Jun 2017 11:00am EDT 

June 12 (Reuters) - Metlife Inc ::Metlife names new Chief Human Resources Officer.Named Susan Podlogar as Executive Vice President and Chief Human Resources Officer.Podlogar comes to Metlife from Johnson & Johnson.  Full Article

Qualcomm announces agreement with Lifescan Inc
Monday, 12 Jun 2017 07:30am EDT 

June 12 (Reuters) - Qualcomm Inc ::Qualcomm announces agreement with Lifescan Inc, a Johnson & Johnson diabetes care company, to inform patient care with connected blood glucose meters.Qualcomm Inc - companies plan to deploy 2NET solution to select physician offices in fall of 2017, and expand globally in 2018.Qualcomm Inc - announces agreement with Lifescan Inc.  Full Article

Tesaro says Janssen updated clinicaltrials.gov website to reflect janssen had placed temporary enrollment hold in the galahad ‍​
Monday, 12 Jun 2017 06:47am EDT 

June 12 (Reuters) - Johnson & Johnson :Tesaro says on June 9, Janssen updated clinicaltrials.gov website to reflect Janssen had placed temporary enrollment hold in the galahad trial ‍​- SEC filing ‍​.Tesaro says galahad trial is not on clinical hold, temporary enrollment hold is not due to any safety concerns.Tesaro says Janssen anticipates re-opening enrollment for galahad trial soon.  Full Article

Johnson & Johnson says expects settlement of Actelion tender offer on June 16, 2017
Friday, 9 Jun 2017 11:30am EDT 

June 9 (Reuters) - Johnson & Johnson : :Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017.Announces receipt of all regulatory approvals required to complete acquisition of Actelion.A Johnson & Johnson subsidiary will initially hold 9.9 percent of shares of Idorsia Ltd.  Full Article

ClinicalTrials.gov says Janssen's study of niraparib suspends recruitment
Friday, 9 Jun 2017 10:54am EDT 

June 9 (Reuters) - ClinicalTrials.gov::Janssen Research's study of niraparib in men with metastatic castration-resistant prostate cancer, DNA-repair anomalies suspended recruitment.Current participants in Janssen Research's study of niraparib remain active and on study treatment.  Full Article

‍Janssen Sciences Ireland UC -VIIV Healthcare made regulatory submissions to EMA,FDA for dolutegravir and rilpivirine​
Thursday, 1 Jun 2017 03:59pm EDT 

June 1 (Reuters) - Johnson & Johnson : :‍Janssen Sciences Ireland UC -VIIV Healthcare made regulatory submissions to EMA,FDA for dolutegravir and rilpivirine​.  Full Article

Photo

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.